ChromaDex broadens NAD+ precursor intellectual property portfolio with patent

ChromaDex announced the broadening of its NAD+ precursor intellectual property portfolio with the newly granted U.S. Patent number 10,000,520 C1 covering the composition of matter for the disodium salt of NMNH or dihydronicotinamide mononucleotide . Co-owned with Queen’s University Belfast QUB , this patent solidifies ChromaDex’s leadership in the NAD+ precursor space. ChromaDex continuously evaluates and investigates next-generation NAD+ precursors at the forefront of the burgeoning healthy aging category. The company owns and licenses a robust and secure portfolio of over 80 patents relating to its flagship patented nicotinamide riboside NR ingredient, Niagen and other NAD+ precursors including nicotinamide riboside triacetate or NRT , reduced nicotinamide riboside NRH , nicotinic acid riboside or NAR, and now the newly granted NMNH patent…In addition to the disodium salt of NMNH, ChromaDex has also obtained protection for numerous other NMNH derivatives, including metallic salts such as lithium, potassium, and magnesium. Further, the patent adds protection for salt forms of NMNH. This broadens ChromaDex’s protection and opens new avenues for future product development and commercialization.